Vercise Genus™ DBS System

Precision takes shape

Clinical Excellence

Vercise DBS systems are supported by dozens of studies with hundreds of patients showing the clinical benefits that the systems provide to patients globally.
tbd

Explore

 

Key Findings

The INTREPID study, the first multi-center, prospective, double blinded, randomized, sham-controlled trial for deep brain stimulation, demonstrated at patients’ one-year follow-up:
6-hr
improvement in on-time1 without troublesome dyskinesia
51 percent
improvement in UPDRS III scores1
34 percent
improvement in quality of life1
41 percent
of programs used more than one contact1
See the Vercise DBS Systems’ clinical data
 

DIRECT DBS Study

92 percent
Multiple Independent Current Control (MICC) and directionality Yielded Optimal Stimulation Settings in 92% of Patients.2

Anodic Stimulation

Anodic
Vercise DBS offers unique anodic stimulation capabilities that are demonstrated to improve efficacy and side effect threshold3.
 

Therapeutic Window

65 percent
larger therapeutic window4 enabled with low pulse width settings combined with Cartesia 3D*
 

 

Precision Delivered

The Vercise Genus DBS System features directional and standard leads powered by Cartesia 3D.

Learn more

Precision Made Personal

All of the system’s IPGs are full-body MR-conditional** and powered by Cartesia 3D directional programming.

Learn more

Precision in Hand

Personalize DBS programming with wireless Bluetooth® communication, intuitive directional steering controls and insightful clinical effect annotations.

Learn more

customer support

Stay up to date

Top